Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Marksans Pharma Ltd. Share Price
Day's Range
Day's Range
Low
₹263.50
High
₹281.60
Price Summary
| Previous Close | ₹276.15 |
|---|---|
| Day's Range | ₹263.50 - ₹281.60 |
| Open | ₹265.30 |
| 52 Week Range | ₹155.00 - ₹278.80 |
| Volume | 25,74,369 |
| Market Cap | ₹0.01 |
| Previous Close | ₹275.75 |
|---|---|
| Day's Range | ₹264.75 - ₹281.40 |
| Open | ₹264.75 |
| 52 Week Range | ₹156.00 - ₹278.20 |
| Volume | 3,14,622 |
| Market Cap | ₹0.01 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 7,109.12 |
|---|---|
| Market Cap (₹ in Mn) | 0.01 |
| Dividend Yield(%) | 0.34 |
| Price/Earning (TTM) | 28.57 |
| TTM EPS (₹) | 9.22 |
| P/E Ratio | 26.48 |
| Book Value(₹) | 3.95 |
| PAT Margin (%) | 13.93 |
| Face Value (₹) | 1.00 |
| ROCE(%) | 22.50 |
| Trade Value ( ₹ in Lacs) | 867.57 |
|---|---|
| Market Cap (₹ in Mn) | 0.01 |
| Dividend Yield(%) | 0.34 |
| Price/Earning (TTM) | 28.57 |
| TTM EPS (₹) | 9.22 |
| P/E Ratio | 26.48 |
| Book Value(₹) | 3.95 |
| PAT Margin (%) | 13.93 |
| Face Value (₹) | 1.00 |
| ROCE(%) | 22.50 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 2993.57 | 26228.45 |
| Expenses | N/A | N/A |
| PBT | 499.03 | 5039.67 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 375.91 | 3826.19 |
About Marksans Pharma Ltd.
| Founded | 1992 |
|---|---|
| Managing Director | Mark Saldanha |
| NSE Symbol | MARKSANS |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,52,982.45 | 1,940.20 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,79,361.19 | 6,887.00 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,64,736.63 | 4,911.95 | 3,307.60 - 3,307.60 |
| Apollo Hospitals Enterprise Ltd. | 1,25,808.70 | 8,860.50 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,15,655.17 | 1,445.80 | 1,165.70 - 1,165.70 |
| Zydus Lifesciences Ltd. | 1,14,613.19 | 1,168.80 | 835.50 - 835.50 |
| Dr. Reddy's Laboratories Ltd. | 1,12,572.73 | 1,297.60 | 1,148.40 - 1,148.40 |
| Lupin Ltd. | 1,12,362.61 | 2,508.95 | 1,836.80 - 1,836.80 |
| Max Healthcare Institute Ltd. | 1,05,561.24 | 1,119.70 | 903.00 - 903.00 |
| Mankind Pharma Ltd. | 1,02,794.70 | 2,547.00 | 1,909.70 - 1,909.70 |
No Records Found
Latest News
Marksans Pharma informs about acquisition
Marksans Pharma has informed that the company entered into a definitive agreement to acquire 100% of the share capital of ABCnow GmbH, a Germany based pharmaceutical company with frontend sales, marketing, and distribution capabilities across German healthcare market. The acquisition marks a strategic step in expanding Marksans' presence across regulated European markets and strengthening its forward-integration strategy through direct, owned market-access capabilities in the European Union. The company has enclosed the details required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/ 4/2015 dated September 9, 2015 given in Annexure A to this letter.
The above information is a part of company’s filings submitted to BSE.
Marksans Pharma informs about press release
Biocon informs about press release
Sigachi Industries informs about non-applicability of certificate
Max Healthcare Institute informs about disclosure
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Marksans Pharma Ltd. is ₹276.15 as of 2026-07-09.
The market capitalisation of Marksans Pharma Ltd. is ₹11,940.86 as of 2026-07-08.
The 1-year return of Marksans Pharma Ltd. is 23.70% as of 2026-07-09.
The P/E ratio of Marksans Pharma Ltd. is 26.48 as of 2026-07-09.
The 52-week high and low of Marksans Pharma Ltd. are ₹278.80 and ₹155.00, respectively, as of 2026-07-09.
People Also Ask
Marksans focuses on oral solid dosages for OTC and prescription markets, especially in the US, UK, and Australia, including pain, cough‑cold, and GI products.
Marksans Pharma collaborates with pharmaceutical companies and retail distributors through contract manufacturing and supply of generic and OTC formulations. Its products are distributed through regulated market supply chains and are used across primary-care treatment settings, including retail and institutional channels.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
